Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data For AM461, A Back-Up To Amira's Lead DP2 Antagonist, AM211
SAN DIEGO, December 3 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM461, the Company's second oral selective antagonist of the…